�鶹Ů��

A year ago, after much fanfare and controversy, the Food and Drug Administration approved Eisai and Biogen’s lecanemab, an anti-amyloid drug that moderately slowed cognitive decline in patients with Alzheimer’s disease. But doctors have been hesitant to prescribe the drug and its pharmacological cousin, Eli Lilly’s donanemab, for people with Down syndrome because of a lack of safety data. (Broderick, 8/21)

Innovative research harnessing the Zika virus to destroy certain cancers is getting a “significant” boost through a $7 million donation to Nemours Children’s Health. The gift from the Pass It on to Kids Foundation, announced Tuesday, will also support the pediatric hospital system’s music therapy program. (Mayer, 8/21)

As periods of extreme heat become more common in North Carolina and across the country, and global heat records keep getting shattered, public policymakers are paying more attention to the impact of climate change on health. A related topic that has been gaining attention only recently is the impact that extreme heat can have on prescription medications in transit — especially when those pharmaceuticals are delivered through mail-order shipments. (Blythe, 8/22)

Digital pharmacy provider Truepill has agreed to be acquired for $525 million by Ireland's LetsGetChecked, Axios has learned from multiple sources. Truepill is a telehealth pioneer, but it's no longer a unicorn. (Primack, 8/21)

An explosion at a pharmaceutical plant in India’s southern state of Andhra Pradesh has killed at least 17 people, according to a government official. A fire broke out following the blast on Wednesday at the privately held Escientia Advanced Sciences’s 40-acre manufacturing unit in the Anakapalli district. The company manufactures intermediate chemicals and active pharmaceutical ingredients, local media reports said. (8/21)